Raymond James analyst Michael Freeman raised the firm’s price target on NervGen Pharma (NGENF) to C$6 from C$4.50 and keeps an Outperform rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGENF:
- NervGen Pharma price target raised to C$5 from C$4.50 at Stifel
- NervGen Pharma Announces Breakthrough Results in Spinal Cord Injury Treatment Trial
- NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291
- NervGen Pharma to Present Promising NVG-291 Study Results at ASIA Meeting
- NervGen Pharma Awards Stock Options to Directors and Employees